A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A Phase 3, Multicenter, Open Label, Randomized Study Of Abarelix Versus Leuprolide Plus Daily Antiandrogen In Men With Prostate Cancer

Published:2002-04 Issue: Volume: Page:1670-1674
ISSN:0022-5347
Container-title:The Journal of Urology
language:en
Short-container-title:The Journal of Urology

Author:

TRACHTENBERG JOHN,GITTLEMAN MARC,STEIDLE CHRISTOPHER,BARZELL WINSTON,FRIEDEL WILLIAM,PESSIS DENNIS,FOTHERINGHAM NICK,CAMPION MARILYN,GARNICK MARC B.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference10 articles.

1. Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

2. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.

3. Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate Cancer

4. Treatment of Advanced Prostatic Cancer

5. THE GONADOTROPIN-RELEASING HORMONE ANTAGONIST ABARELIX DEPOT VERSUS LUTEINIZING HORMONE RELEASING HORMONE AGONISTS LEUPROLIDE OR GOSERELIN: INITIAL RESULTS OF ENDOCRINOLOGICAL AND BIOCHEMICAL EFFICACIES IN PATIENTS WITH PROSTATE CANCER

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Plasma Metabolic Profiles-Based Prediction of Induction Chemotherapy Efficacy in Nasopharyngeal Carcinoma: Results of a Bidirectional Clinical Trial;Clinical Cancer Research;2024-05-07

2. Targeting sex steroid biosynthesis for breast and prostate cancer therapy;Nature Reviews Cancer;2023-09-08

3. Physiological and pharmacological overview of the gonadotropin releasing hormone;Biochemical Pharmacology;2023-06

4. Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study;BMC Medicine;2023-04-03

5. The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer;Bioorganic & Medicinal Chemistry Letters;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3